Capricorn, Vesalius lead round for Trod

Other investors in the round included Flemish investment company PMV and the Gemma Frisius Fund, a seed capital fund that span out of the University of Leuven in partnership with BNP Paribas and KBC Group in 1997.

Vesalius backed the company via its Vesalius Biocapital II Arkiv fund, which held its first close on €50m in January 2011, according to unquote" data. Capricorn invested via its Capricorn Health-tech Fund.

The capital injection will be used by Trod to carry out clinical studies of its Encage technology, which is designed for use in the focal treatment of prostate cancer, in both Europe and the US.

Company
Founded in 2006, Trod has relocated its headquarters to Leuven in conjunction with the funding round. Prior to the round, Trod was headquartered in Paris. The company has an additional office in Florida.

Trod develops radio frequency ablation devices. The company's Encage technology is a radio frequency-based device designed to allow precise soft tissue ablation for the treatment of diseases such as cancer spots in the prostate.

The technology is designed to deliver focal treatment of prostate cancer with a reduction in side effects such as impotence and incontinence. The technology has already gone through a pilot study, described by Trod as successful.

People
Andre Faure is the CEO of Trod. Stéphane Verdood is a managing partner and co-founder of Vesalius, while Frank Bulens is a partner at Capricorn. Both Verdood and Bulens have joined Trod's board of directors.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Early-stage
• Healthcare
• Belgium